Breast tissue: nootropics and compounds | sci-wiki

Y-134

Y-134 is a research-stage selective estrogen receptor modulator (SERM) engineered by fine-tuning the well-known drug raloxifene. Beyond the classic SERM profile of blocking estrogen in breast tissue while supporting bone, Y-134 carries a striking bonus: it switches on the aryl hydrocarbon receptor (AhR) and drives even hard-to-treat triple-negative breast cancer cells into programmed cell death, an effect its parent compound only hinted at. Elegant and highly selective, it is prized as a research tool, though it remains preclinical with no human data.

1 outlet

SERM

4-Hydroxytamoxifen

4-Hydroxytamoxifen (afimoxifene, 4-OHT) is the potent active metabolite of tamoxifen and one of the most powerful selective estrogen receptor modulators available, binding the estrogen receptor with far greater affinity than tamoxifen itself. Prized across clinical research and hormonal management, it shuts down estrogen signaling in breast tissue while behaving tissue-selectively elsewhere. It is also a cornerstone laboratory reagent, valued for switching on tamoxifen-inducible genetic systems with precision.

1 outlet

SERM

Endoxifen

Endoxifen is the most potent active metabolite of the breast cancer drug tamoxifen, a powerful antiestrogen that does much of tamoxifen's real work inside the body [1]. Because the body relies on the enzyme CYP2D6 to make it, blood endoxifen levels vary widely between people and strongly predict how well tamoxifen works, which has driven efforts to monitor levels and to give endoxifen directly as a drug [2][3]. For precision in estrogen-driven disease, endoxifen is a compound of intense and growing clinical interest.

1 outlet

SERM

Raloxifene

Raloxifene is a benzothiophene selective estrogen receptor modulator (SERM) that binds both estrogen receptor subtypes with high affinity yet behaves as an agonist in some tissues and an antagonist in others. The molecular basis for this tissue selectivity is elegant: the bound ligand imposes a distinct conformation on the receptor that governs which coactivator or corepressor proteins are recruited at a given gene promoter, so the same drug preserves bone density and improves the lipid profile while blocking estrogen's proliferative signal in breast and endometrial tissue. Clinically it is used to prevent and treat postmenopausal osteoporosis and to lower the risk of invasive breast cancer in higher-risk women, a dual profile supported by the MORE, CORE, RUTH, and STAR trials. Because it does not stimulate the uterus, raloxifene carries a more favorable endometrial safety profile than tamoxifen, though it shares an increased risk of venous thromboembolism.

1 outlet